Sfoglia per AUTORE
GORI S
Collezione AOU Novara

  

Items : 13

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.

2022
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Russo A; Russano M; Tiseo M; Porzio G; Ficorella C; Addeo A; Friedlaender A; Banna GL; Passiglia F; Spinelli GP; Metro G; Migliorino MR; Zoratto F; Ricciardi S; Mansueto G; Pecci F; Di Marino P; Gori S; De Tursi M; Tuzi A; Della Gravara L; Rastelli F; Macerelli M; Gelibter A; Chiari R; Marchetti P; Antonuzzo L; Mazzoni F; Genova C; et alii...

Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ?50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. in Thoracic cancer / Thorac Cancer. 2022 Feb;13(3):483-488. doi: 10.1111/1759-7714.14256. Epub 2021 Dec 22.

2022
ASL Città di Torino
AOU Novara

Cortellini A; Addeo A; Pinato DJ; Porzio G; Ficorella C; Pensieri MV; Friedlaender A; Metro G; De Toma A; Cappuzzo F; Bertolini F; Rijavec E; Citarella F; Cantini L; Mansueto G; Gori S; Macerelli M; Chiari R; Rastelli F; Gelibter A; Mazzoni F; Catino A; Genova C; Morabito A; Grossi F; Berardi R; Bria E; Giusti R; Baldessari C; et alii...

PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. in Breast (Edinburgh, Scotland) / Breast. 2022 Dec;66:293-304. doi: 10.1016/j.breast.2022.10.014. Epub 2022 Oct 29.

2022
ASL Città di Torino
AOU Novara

Levaggi A; Delle Piane C; Biganzoli L; Zambelli A; Del Mastro L; Montemurro F; Criscitiello C; Cortesi L; Dieci MV; Cinquini M; Miglietta F; Marchiò C; Calabrese M; Fortunato L; Franco P; Meduri B; Fittipaldo VA; Gori S;

Combi-TED: a new trial testing Tedopi(®) with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. in Future oncology (London, England) / Future Oncol. 2022 Dec;18(40):4457-4464. doi: 10.2217/fon-2022-0913. Epub 2023 Mar 22.

2022
AOU Novara

Landi L; Delmonte A; Bonetti A; Pasello G; Metro G; Mazzoni F; Borra G; Giannarelli D; Andrikou K; Mangiola D; Gori S; D'Andrea MR; Minuti G; Resuli B; Laudisi A; Vidiri A; Conti L; Cappuzzo F;

Corrigendum: Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors. in Frontiers in oncology / Front Oncol. 2022 Feb 2;12:851999. doi: 10.3389/fonc.2022.851999. eCollection 2022.

2022
AOU Novara

Caprara G; Tieri M; Fabi A; Guarneri V; Falci C; Dieci MV; Turazza M; Ballardini B; Bin A; Cinieri S; Vici P; Montagna E; Zamagni C; Mazzi C; Modena A; Marchetti F; Verzè M; Ghelfi F; Titta L; Nicolis F; Gori S;

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.

2021
AOU San Luigi di Orbassano
AO Ordine Mauriziano
AOU Novara

Russo A; Adamo V; Metro G; De Filippis M; Simona C; Natalizio S; Migliorino MR; Ricciardi S; Landi L; Minuti G; Buti S; Nigro O; Cantini L; Russano M; Citarella F; Bracarda S; Filetti M; Zoratto F; Mansueto G; De Tursi M; Gori S; Rocco D; Chiari R; Rastelli F; Gelibter A; Targato G; Signorelli D; De Toma A; Mazzoni F; et alii...

PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. in Journal of translational medicine / J Transl Med. 2021 Jun 24;19(1):270. doi: 10.1186/s12967-021-02937-9.

2021
AOU Novara

Santini D; Zeppola T; Russano M; Citarella F; Anesi C; Buti S; Tucci M; Russo A; Sergi MC; Adamo V; Stucci LS; Bersanelli M; Mazzaschi G; Spagnolo F; Rastelli F; Giorgi FC; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Siringo M; Ferrari M; Marconcini R; Vitale MG; Nicolardi L; Chiari R; Ghidini M; Nigro O; et alii...

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Cannita K; Porzio G; Friedlaender A; Addeo A; Banna GL; Spinelli GP; Russo A; Adamo V; Metro G; Olmetto E; Tabbò F; Migliorino MR; Ricciardi S; Landi L; Minuti G; Tuzi A; Bisonni R; Follador A; Siringo M; Gelibter A; Signorelli D; De Toma A; Garassino MC; Mazzoni F; Russano M; Citarella F; Filetti M; Zoratto F; Mansueto G; et alii...

Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors. in Frontiers in oncology / Front Oncol. 2021 Nov 1;11:705927. doi: 10.3389/fonc.2021.705927. eCollection 2021.

2021
AOU Novara

Caprara G; Tieri M; Fabi A; Guarneri V; Falci C; Dieci MV; Turazza M; Ballardini B; Bin A; Cinieri S; Vici P; Montagna E; Zamagni C; Mazzi C; Modena A; Marchetti F; Verzè M; Ghelfi F; Titta L; Nicolis F; Gori S;

An integrated care pathway for cancer patients with diabetes: A proposal from the Italian experience. in Diabetes research and clinical practice / Diabetes Res Clin Pract. 2020 Jan;159:107721. doi: 10.1016/j.diabres.2019.04.036. Epub 2019 May 11.

2020
AOU Città della Salute di Torino
AOU Novara

Mannino D; Gori S; Musacchio N; Pinto C; Russo A; Candido R; Chantal Ponziani M; Farci D; Michelini M; Suraci C; Clemente G; Cristiano Corsi D; Gallo M;

Correction to: Standard (8?weeks) vs long (12?weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). in BMC cancer / BMC Cancer. 2020 Feb 17;20(1):128. doi: 10.1186/s12885-020-6632-y.

2020
ASL Biella
AO Alessandria
AOU Novara

Franzone P; Numico G; Priora F; Rossi M; Fusco V; Traverso E; Torri V; Cavaliere D; Solaini L; Ercolani G; Ceccarelli C; Balestri R; Buccianti P; Baroffio P; Gentilli S; Menegatti B; Coratti A; Perna F; Rosati R; Delpini R; Elmore U; Mammano E; Contardo T; Morpurgo E; Perinotti R; De Nisco C; Pulighe F; Pernazza G; Boni L; et alii...

Standard (8?weeks) vs long (12?weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). in BMC cancer / BMC Cancer. 2019 Dec 16;19(1):1215. doi: 10.1186/s12885-019-6271-3.

2019
ASL Biella
AO Alessandria
AOU Novara

Orecchia S; Numico G; Franzone P; Priora F; Rossi M; Fusco V; Traverso E; Ercolani G; Cavaliere D; Solaini L; Torri V; Ceccarelli C; Buccianti P; Balestri R; Menegatti B; Gentilli S; Baroffio P; Perna F; Coratti A; Delpini R; Rosati R; Elmore U; Mammano E; Pulighe F; De Nisco C; Perinotti R; Morpurgo E; Boni L; Contardo T; et alii...

The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. in PloS one / PLoS One. 2015 Sep 4;10(9):e0136731. doi: 10.1371/journal.pone.0136731. eCollection 2015.

2015
ASL Cuneo 1
AO Cuneo
AOU Novara

Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L; Gamucci T; Evangelisti L; Barni S; Saracchini S; Amaducci L; Santini D; Fabi A; Garrone O; Frassoldati A; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Spazzapan S; Iezzi L; De Simone V; Duranti S; Cavazzini MG; Turazza M; Gubiotti M; Foglietta J; et alii...